Juliet Morrison, PhD

Associate Research Scientist
Phone: 212.305.8178
Fax: 212.342.9044
Email: jmm2105@columbia.edu




Bard College, Annandale-on-Hudson, NY, B.A., 2003
Columbia University, New York, NY, Ph.D., 2009


Combining computational analysis and traditional virological methods to address questions at the host-pathogen interface
Using gene expression signatures to predict outcomes of infection and vaccination
Host-targeted therapeutics to ameliorate severe influenza and flavivirus disease


Dr. Juliet Morrison is an Associate Research Scientist at the Center for Infection and Immunity at Columbia University’s Mailman School of Public Health, where she specializes in combining computational analysis with immunological and virological methods to address questions at the host-pathogen interface. She leads collaborative influenza research projects under a large NIH subcontract while conducting systems-level research pertaining to emerging and re-emerging pathogens. She has spent the last 14 years studying innate immune responses to viral pathogens such as dengue virus, rhinovirus, poliovirus, yellow fever virus and influenza virus. During her graduate studies at Columbia University, she discovered that a viral protease facilitated poliovirus and rhinovirus interferon resistance. During her postdoctoral training at Icahn School of Medicine at Mount Sinai, she discovered and characterized two novel and disparate mechanisms whereby the NS5 proteins of dengue virus and yellow fever virus inhibit interferon signaling to enhance viral replication and pathogenesis. At the University of Washington, Dr. Morrison showed that influenza disease severity correlates with host transcriptional signatures of increased cytokine production, and decreased coagulation and lipid metabolism signaling.

In recent projects, Dr. Morrison has employed tissue deconvolution algorithms and immunological tools to study the dynamics of lung immune cell populations in influenza virus infections, and spleen and liver immune cell populations in dengue virus infections. By blending computational and experimental methods, she was able to identify a novel macrophage population that may play a role in influenza recovery. She is now working to understand how this population impacts influenza outcomes, and how its functions are regulated.  Dr. Morrison’s research is designed to be rapidly translated into host-targeted influenza virus and flavivirus therapeutics.


  • Juliet Morrison, Abhay P. S. Rathore, Chinmay K. Mantri, Siti A. B. Aman, Andrew Nishida, and Ashley L. St. John. Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model. 2017. Journal of Virology. 91:e00617-17.
  • Juliet Morrison and Stanley Plotkin. Chapter 19: Viral vaccines and systems vaccinology. 2016. Viral Pathogenesis: From Basics to Systems Biology, 3rd Edition. Elsevier
  • Juliet Morrison and Michael G. Katze. Gene expression signatures as a therapeutic target for severe H7N9 influenza - what do we know so far? 2015. Expert Opinion on Therapeutic Targets 19(4): 447-4509. PMID: 25600759
  • Juliet Morrison, Laurence Josset, Nicolas Tchitchek, Jean Chang, Jessica A. Belser, David E. Swayne, Mary J. Pantin-Jackwood, Terrence M. Tumpey and Michael G. Katze. H7N9 and other pathogenic avian influenza viruses elicit a three-pronged transcriptomic signature that is reminiscent of 1918 influenza and associated with lethal outcome in mice. 2014. Journal of Virology 88(18):10556-68. PMID: 24991006
  • Maudry Laurent-Rolle*, Juliet Morrison*, Ricardo Rajsbaum, Jesica M. Macleod, Giuseppe Pisanelli, Alissa Pham, Juan Ayllon, Lisa Miorin, Carles Martınez-Romero, Ben TenOever and Adolfo García-Sastre. The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. 2014. Cell Host and Microbe 16(3):314-27. PMID: 25211074 *authors contributed equally
  • Juliet Morrison and Adolfo García-Sastre. STAT2 signaling and dengue virus infection. 2014. JAKSTAT 3(1):e27715
  • Juliet Morrison*, Maudry Laurent-Rolle*, Ana Maestre, Ricardo Rajsbaum, Giuseppe Pisanelli, Viviana Simon, Lubbertus Mulder, Ana Fernandez-Sesma and Adolfo García-Sastre. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I IFN signaling. 2013. PLOS Pathogens 9(3): e1003265. PMID: 23555265 *authors contributed equally
  • Joseph Ashour, Juliet Morrison, Maudry Laurent-Rolle, Alan Belicha-Villanueva, Courtney Ray Plumlee, Dabeiba Bernal, Kate Williams, Eva Harris, Ana Fernandez-Sesma, Christian Schindler and Adolfo García-Sastre. Mouse STAT2 restricts early dengue virus replication. 2010. Cell Host and Microbe 18;8(5): 410-21. PMID: 21075352
  • Juliet Morrison and Vincent Racaniello. Proteinase 2Apro is essential for enterovirus replication in type I interferon-treated cells. 2009. Journal of Virology 83 (9): 4412-22. PMID: 19211759
  • Feng Lin*, Juliet Morrison*, Wei Wu* and Howard Worman. Man1, an integral membrane protein of the inner membrane, binds Smad2 and Smad3 and antagonizes transforming growth factor beta signaling. 2005. Human Molecular Genetics 14(3): 437-445. PMID: 15601644 *authors contributed equally